MINARIK, Jiri, Viera SANDECKÁ, Vladimír MAISNAR, Evzen GREGORA, Ivan SPICKA, David STAROSTKA, Hana PLONKOVÁ, Jiří JARKOVSKÝ, Lenka WALTEROVA, Marek WROBEL, Dagmar ADAMOVÁ, Tomas PIKA, Hana MELICHAROVÁ, Ludek POUR, Jakub RADOCHA, Petr PAVLICEK, Jan STRAUB, Jaromir GUMULEC, Jaroslav BAČOVSKÝ, Zdeněk ADAM, Vlastimil SCUDLA a Roman HAJEK. 10 years of experience with thalidomide in multiple myeloma patients: Report of the Czech Myeloma Group. Leukemia Research. OXFORD: PERGAMON-ELSEVIER SCIENCE LTD, roč. 37, č. 9, s. 1063-1069. ISSN 0145-2126. doi:10.1016/j.leukres.2013.06.019. 2013. |
Další formáty:
BibTeX
LaTeX
RIS
@article{1137370, author = {Minarik, Jiri and Sandecká, Viera and Maisnar, Vladimír and Gregora, Evzen and Spicka, Ivan and Starostka, David and Plonková, Hana and Jarkovský, Jiří and Walterova, Lenka and Wrobel, Marek and Adamová, Dagmar and Pika, Tomas and Melicharová, Hana and Pour, Ludek and Radocha, Jakub and Pavlicek, Petr and Straub, Jan and Gumulec, Jaromir and Bačovský, Jaroslav and Adam, Zdeněk and Scudla, Vlastimil and Hajek, Roman}, article_location = {OXFORD}, article_number = {9}, doi = {http://dx.doi.org/10.1016/j.leukres.2013.06.019}, keywords = {Multiple myeloma; Thalidomide; Response rate; Prognostic factors; Combined regimens; Adverse events}, language = {eng}, issn = {0145-2126}, journal = {Leukemia Research}, title = {10 years of experience with thalidomide in multiple myeloma patients: Report of the Czech Myeloma Group}, volume = {37}, year = {2013} }
TY - JOUR ID - 1137370 AU - Minarik, Jiri - Sandecká, Viera - Maisnar, Vladimír - Gregora, Evzen - Spicka, Ivan - Starostka, David - Plonková, Hana - Jarkovský, Jiří - Walterova, Lenka - Wrobel, Marek - Adamová, Dagmar - Pika, Tomas - Melicharová, Hana - Pour, Ludek - Radocha, Jakub - Pavlicek, Petr - Straub, Jan - Gumulec, Jaromir - Bačovský, Jaroslav - Adam, Zdeněk - Scudla, Vlastimil - Hajek, Roman PY - 2013 TI - 10 years of experience with thalidomide in multiple myeloma patients: Report of the Czech Myeloma Group JF - Leukemia Research VL - 37 IS - 9 SP - 1063-1069 EP - 1063-1069 PB - PERGAMON-ELSEVIER SCIENCE LTD SN - 01452126 KW - Multiple myeloma KW - Thalidomide KW - Response rate KW - Prognostic factors KW - Combined regimens KW - Adverse events N2 - We analyzed 1156 multiple myeloma (MM) patients treated with thalidomide. The overall response rate was 63.6%, with complete remission in 13.4%. Combined regimens had better outcomes than thalidomide plus dexamethasone or single agent thalidomide. Thalidomide was not able to overcome adverse cytogenetics. Superior results were seen in patients undergoing subsequent autologous stem cell transplantation. The rate of adverse events was low. Thalidomide has a strong potential to improve response and survival measures in patients with standard risk MM. Combined regimens should be used, with lower doses of thalidomide. High risk myelomas should be treated individually. ER -
MINARIK, Jiri, Viera SANDECKÁ, Vladimír MAISNAR, Evzen GREGORA, Ivan SPICKA, David STAROSTKA, Hana PLONKOVÁ, Jiří JARKOVSKÝ, Lenka WALTEROVA, Marek WROBEL, Dagmar ADAMOVÁ, Tomas PIKA, Hana MELICHAROVÁ, Ludek POUR, Jakub RADOCHA, Petr PAVLICEK, Jan STRAUB, Jaromir GUMULEC, Jaroslav BAČOVSKÝ, Zdeněk ADAM, Vlastimil SCUDLA a Roman HAJEK. 10 years of experience with thalidomide in multiple myeloma patients: Report of the Czech Myeloma Group. \textit{Leukemia Research}. OXFORD: PERGAMON-ELSEVIER SCIENCE LTD, roč.~37, č.~9, s.~1063-1069. ISSN~0145-2126. doi:10.1016/j.leukres.2013.06.019. 2013.
|